Antiviral therapy in neonatal cholestatic cytomegalovirus hepatitis

Basit Öğe Kaydı
dc.contributor.authorÖzkan, Tanju Başarır
dc.contributor.authorMıstık, Reşit
dc.contributor.authorDikici, Bünyamin
dc.contributor.authorNazlıoğlu, Hülya Öztürk
dc.date.accessioned2020-04-30T22:39:31Z
dc.date.available2020-04-30T22:39:31Z
dc.date.issued2007
dc.departmentDÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.descriptiondikici, bunyamin/0000-0001-7572-6525en_US
dc.descriptionWOS: 000245455600001en_US
dc.descriptionPubMed: 17355631en_US
dc.description.abstractBackground: Neonatal hepatitis refers to a heterogeneous group of disorders, caused by many factors including cytomegalovirus infection, revealing similar morphologic changes in the liver of an infant less than 3 months of age. Approximately 40% of cholestasis in infants is due to neonatal hepatitis. It may cause latent or acute cholestatic or chronic hepatitis, including cirrhosis in immunocompetant infant. Methods: Twelve infants diagnosed with neonatal cytomegalovirus hepatitis in the last one year were included in the study. Group 1 consisted of seven babies treated with ganciclovir for 21 days. Group 2 included five cases who did not receive antiviral treatment. Physical examination, biochemical, serologic and virologic tests were done for both groups at the time of diagnosis and in the third month. Results: Initial levels of total bilirubin, aminotransferases, gamma glutamyl transpeptidase, and alkaline phosphatase revealed a significant decrease after the treatment in Group 1 ( p < 0.05) when compared with Group 2. This study revealed that ganciclovir treatment is a safe and effective in cases with cholestatic hepatitis. Similarly, all the patients in the treatment group had evidence of improvement serologically and virologically, while the comparison group did not reveal any significant change( p < 0.01). Conclusion: The clinical spectrum of perinatal infection varies from an asymptomatic infection or a mild disease to a severe systemic involvement, including central nervous system. The treatment in the early period of infection improved serologic markers and cholestatic parameters significantly. Further studies will lead us to clarify the efficacy of ganciclovir treatment in the early period of cytomegalovirus hepatitis, and the preventive role of anti-viral therapy on progressive liver disease due to cholestasis and hepatitis in neonatal cytomegalovirus infection.en_US
dc.identifier.doi10.1186/1471-230X-7-9en_US
dc.identifier.issn1471-230X
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1186/1471-230X-7-9
dc.identifier.urihttps://hdl.handle.net/20.500.12684/2747
dc.identifier.volume7en_US
dc.identifier.wosWOS:000245455600001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherBmcen_US
dc.relation.ispartofBmc Gastroenterologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleAntiviral therapy in neonatal cholestatic cytomegalovirus hepatitisen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
2747.pdf
Boyut:
479.26 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu